中文简体
中文繁体
English
العربية
ABOUT IASO
Company Overview
Management Team
Scientific Advisory Board
Partnership
SCIENCE & PRODUCTS
Pipeline
Technology Platforms
Manufacturing
Publictaions
Expanded Access
NEWS
Press Release
Media Report
CAREERS
Working at IASO
Opportunities
CONTACT
NEWS
Press Release
Media Report
Search
17/09
2026
IASO Bio’s CD20-targeted in vivo CAR-T cleared for US study in B-NHL
17/09
2026
IASO208 Receives FDA IND Clearance for Relapsed/Refractory B-Cell Lymphoma
20/11
2025
GC Cell introduces multiple myeloma CAR-T therapy from China's IASO Biotech
01
2025-07
IASO Bio's Equecabtagene Autoleucel Gains First Approval Outside Mainland China
28
2025-03
Macau approves IASO Bio's multiple myeloma therapy
12
2024-08
IASO Bio Receives U.S. FDA Approval Of Investigational New Drug Application For Equecabtagene Autoleucel For Two New Autoimmune Disease Indications
17
2023-01
IASO Bio Raises Nearly $75 Million in Series C1 Funding
23
2021-09
Fierce Biotech | China's IASO nets $108M to advance cell therapies, antibodies for cancer, autoimmune disease
12
2021-08
PRECISIOIN ONCOLOGY NEWS: In Brief This Week-IASO Biotherapeutics, Genentech, BioNTech
09
2021-06
Trailing the Big Pharma players, a lesser known BCMA CAR-T candidate comes into the spotlight
<
1
2
>
